- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03267108
A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Allison Gladden
- Phone Number: 908.574.4859
- Email: allison.gladden@bellerophon.com
Study Contact Backup
- Name: Dominique Duchesne
- Phone Number: 908.500.2661
- Email: dominique.duchesne@bellerophon.com
Study Locations
-
-
British Columbia
-
Vancouver, British Columbia, Canada, V5Z 1M9
- University of British Columbia
-
-
Ontario
-
Kingston, Ontario, Canada, K7L 5G2
- Queen's University/Hotel Dieu Hospital
-
London, Ontario, Canada, K7L 2V6
- London Health Sciences Centre
-
-
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama
-
-
Arizona
-
Phoenix, Arizona, United States, 85012
- Arizona Pulmonary Specialists, Ltd.
-
Phoenix, Arizona, United States, 85006
- Banner - University Medical Center Arizona
-
-
California
-
Fresno, California, United States, 93701
- University of California San Francisco
-
Los Angeles, California, United States, 90024
- University of California
-
Northridge, California, United States, 91324
- Amicis Research
-
Paloma, California, United States, 92675
- Paloma Medical Group
-
Sacramento, California, United States, 95817
- University of California Davis Health
-
Stanford, California, United States, 94305
- Stanford University Medical Center
-
-
Colorado
-
Aurora, Colorado, United States, 80046
- UC Denver Anschutz Medical Center
-
Denver, Colorado, United States, 80206
- National Jewish
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20007
- Georgetown University
-
-
Florida
-
Clearwater, Florida, United States, 33765
- St. Francis Sleep Allergy and Lung Institute
-
Loxahatchee Groves, Florida, United States, 33470
- Advanced Pulmonary Research Institute
-
Miami, Florida, United States, 33125
- University of Miami
-
Pensacola, Florida, United States, 32503
- Avanza Medical Research Center
-
Tampa, Florida, United States, 33612
- University of South Florida
-
Weston, Florida, United States, 33331
- Cleveland Clinic
-
-
Georgia
-
Atlanta, Georgia, United States, 30322
- Emory University
-
Atlanta, Georgia, United States, 30342
- Northside Hospital
-
Austell, Georgia, United States, 30106
- Piedmont Healthcare
-
-
Illinois
-
Chicago, Illinois, United States, 60611
- Northwestern
-
Evanston, Illinois, United States, 60201
- North Shore University Hospital
-
Maywood, Illinois, United States, 60153
- Loyola University
-
Springfield, Illinois, United States, 62702 / 62794
- Southern Illinois University
-
-
Indiana
-
Indianapolis, Indiana, United States, 46260
- Ascension St. Vincent Hospital
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
Louisville, Kentucky, United States, 40202
- Norton Pulmonary Specialists
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins Hospital
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
Boston, Massachusetts, United States, 02111
- Tufts Medical Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
Detroit, Michigan, United States, 48202
- Henry Ford Hospital
-
-
Missouri
-
Chesterfield, Missouri, United States, 63017
- The Lung Research Center, LLC
-
-
Nebraska
-
Omaha, Nebraska, United States, 68124
- Creighton University
-
-
New Jersey
-
Summit, New Jersey, United States, 07901
- Atlantic Health Respiratory Institute
-
-
New York
-
New York, New York, United States, 10029
- Mount Sinai Hospital
-
New York, New York, United States, 10065
- Weill Cornell Medical Center
-
New York, New York, United States, 10016
- NYU Langone
-
Stony Brook, New York, United States, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Chapel Hill, North Carolina, United States, 27517
- The University of North Carolina at Chapel Hill Marsico Clinical Research Center
-
Greensboro, North Carolina, United States, 27403
- Pulmonix, LLC/LeBauer Cone Health
-
-
Ohio
-
Cincinnati, Ohio, United States, 45267
- University of Cincinnati
-
Cleveland, Ohio, United States, 44106
- University Hospitals
-
Columbus, Ohio, United States, 43210
- The Ohio State University
-
-
Oregon
-
Portland, Oregon, United States, 97220
- The Oregon Clinic
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19104
- University of Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19140
- Temple University
-
Philadelphia, Pennsylvania, United States, 19017
- Thomas Jefferson University Korman Respiratory Institute
-
Pittsburgh, Pennsylvania, United States, 15123
- University of Pittsburgh
-
-
South Carolina
-
Anderson, South Carolina, United States, 29621
- AnMed Health
-
Charleston, South Carolina, United States, 29425
- Medical University of South Carolina
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Dallas, Texas, United States, 75390
- UT Southwestern Medical Center
-
Dallas, Texas, United States, 75246
- Baylor University Medical Center
-
Houston, Texas, United States, 77030
- University of Texas Health Science Center at Houston
-
McKinney, Texas, United States, 75069
- Metroplex Pulmonary and Sleep
-
-
Utah
-
Salt Lake City, Utah, United States, 84108
- University of Utah Health Sciences
-
-
Virginia
-
Falls Church, Virginia, United States, 22042
- Inova Heart and Vascular Institute Advanced Lung Disease Clinic
-
Richmond, Virginia, United States, 23229
- Pulmonary Associates of Richmond
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion criteria:
A high resolution CT scan performed in the 6 months prior to screening associated with one of the following conditions and confirmed using guidelines, as per American Thoracic Society (ATS) / European Respiratory Society (ERS) / Japanese Respiratory Society (JRS) / Latin American Thoracic Association (ALAT):
Major IIPs (idiopathic interstitial pneumonias) diagnosis or suspected as one of the following:
- Idiopathic pulmonary fibrosis
- Idiopathic nonspecific interstitial pneumonia
- Respiratory bronchiolitis-interstitial lung disease
- Desquamative interstitial pneumonia
- Cryptogenic organizing pneumonia
- Acute interstitial pneumonia
Rare IIPs diagnosis by one of the following:
- Idiopathic lymphoid interstitial pneumonia
- Idiopathic pleuroparenchymal fibroelastosis
Unclassifiable idiopathic interstitial pneumonias
- Chronic hypersensitivity pneumonitis
- Occupational lung disease
- Connective Tissue Disease associated with IPF (CTD-ILD)
- Interstitial Pneumonia with Autoimmune Features (IPAF)
- Have been using oxygen therapy by nasal cannula for at least 4 weeks (including use limited to exertion)
- 6MWD ≥ 100 meters and ≤ 400 meters at screening and Baseline/Randomization visits.
- World Health Organization (WHO) Functional Class II-IV
- Forced Vital Capacity ≥ 40% predicted within the 60 day Screening period
- Age between 18 and 80 years (inclusive) at screening
Exclusion criteria:
- For women of child-bearing potential: Pregnant or breastfeeding females at Screening, or planning to get pregnant, or unwilling to use appropriate contraception if sexually active to avoid pregnancy during the study and for at least 30 days after discontinuation of the study drug.
- Heart failure with reduced ejection fraction (HFrEF; systolic heart failure) with an ejection fraction of < 40%; or severe HF with preserved EF (HFpEF; diastolic HF)
- History of sarcoidosis
- History of chronic thrombo-embolic pulmonary hypertension (CTEPH; WHO group 4 PH)
- Smoking within 3 months of Screening and/or unwilling to avoid smoking throughout the study
- Body mass index (BMI) >40 kg/m2 at screening
- Intermittent uncontrolled atrial fibrillation, in the opinion of the Principal Investigator
- Known severe hepatic impairment, in the opinion of the Principal Investigator
- Known severe renal impairment (Chronic Kidney Disease Epidemiology Collaboration (CKDEPI) 2009 equation [Levy 2009] calculated creatinine clearance <30 ml/min) at screening
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Inhaled Nitric Oxide (iNO)
Pulsed inhaled iNO 45 mcg/kg Ideal Body Weight (IBW)/hour (hr)
|
Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
|
Placebo Comparator: Placebo
Pulsed inhaled N2, 99.999% gas
|
Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
|
Other: Open Label Extension
Pulsed inhaled iNO 45 mcg/kg IBW/hr
|
Subjects will be treated by means of an INOpulse® device using an INOpulse® nasal cannula.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Moderate to Vigorous Physical Activity (MVPA) as Measured by Actigraphy
Time Frame: Baseline to Month 4
|
Part 1 - Blinded Treatment Period
|
Baseline to Month 4
|
Adverse Events and Serious Adverse Events with Long Term INOpulse Therapy
Time Frame: Baseline to Month 4
|
Part 2 - Open Label Extension (OLE)
|
Baseline to Month 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Overall Activity as Measured by Actigraphy
Time Frame: Baseline to M4
|
Part 1 - Blinded Treatment Period
|
Baseline to M4
|
Change in University of California San Diego (UCSD) Shortness of Breath Questionnaire (SOBQ)
Time Frame: Baseline to Month 4
|
Part 1 Blinded Treatment Period: The UCSD SOBQ is a 24-item questionnaire developed to measure breathlessness associated with activities of daily living, on a scale between zero and five where 0 is not at all breathless and 5 is maximally breathless or too breathless to do the activity.
The responses to all items are summed up to provide the overall score that can range from 0 (best outcome) to 120 (worst outcome).
|
Baseline to Month 4
|
Change in St. George Respiratory Questionnaire (SGRQ) - Activity, Impacts & Total
Time Frame: Baseline to Month 4
|
Part 1 Blinded Treatment Period: SGRQ is a tool for assessing quality of life that has previously been validated for the use with patients with interstitial lung disease.
It is a responsive tool that has three domains: symptoms, activity and impact (on daily life)
|
Baseline to Month 4
|
Time to Clinical Worsening
Time Frame: Baseline to Month 4
|
Part 1 - Blinded Treatment Period
|
Baseline to Month 4
|
Time to Clinical Deterioration
Time Frame: Baseline to Month 4
|
Part 1 Blinded Treatment Period
|
Baseline to Month 4
|
Time to Clinical Improvement
Time Frame: Baseline to Month 4
|
Part 1 Blinded Treatment Period
|
Baseline to Month 4
|
Change in 6 Minute Walk Distance
Time Frame: Baseline to Month 4
|
Part 1 Blinded Treatment Period
|
Baseline to Month 4
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Ashika Ahmed, Bellerophon Therapeutics
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PULSE-PHPF-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Fibrosis
-
St. Antonius HospitalZonMw: The Netherlands Organisation for Health Research and Development; Boeringer...RecruitingPulmonary Fibrosis Idiopathic FamilialNetherlands
-
Wake Forest University Health SciencesMayo Clinic; The University of Texas Health Science Center at San AntonioCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Sheba Medical CenterUnknownIDIOPATHIC PULMONARY FIBROSISIsrael
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruitingIdiopathic Pulmonary Fibrosis | Pulmonary Disease | Pulmonary MedicineFrance
-
Theravance BiopharmaTerminatedIdiopathic Pulmonary Fibrosis (IPF)United Kingdom
-
University of California, San FranciscoCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
BiogenCompletedIdiopathic Pulmonary Fibrosis (IPF)United States
-
Liminal BioSciences Ltd.CompletedIdiopathic Pulmonary Fibrosis (IPF)Canada
-
Centre Hospitalier Universitaire de NiceRecruitingPulmonary Disease, Chronic Obstructive | Interstitial Pulmonary FibrosisFrance
-
Angion Biomedica CorpNot yet recruitingIdiopathic Pulmonary Fibrosis (IPF)
Clinical Trials on INOpulse®
-
BellerophonActive, not recruitingPulmonary Fibrosis | Pulmonary HypertensionUnited States
-
Bellerophon Pulse TechnologiesCompletedChronic Obstructive Pulmonary Disease | Pulmonary HypertensionUnited States
-
BellerophonAvailablePulmonary Fibrosis | Pulmonary Hypertension
-
Bellerophon Pulse TechnologiesTerminatedCOVID-19 | Coronavirus Infection | CoronavirusUnited States
-
BellerophonCompletedPulmonary Fibrosis | Pulmonary Hypertension | Sarcoidosis, PulmonaryUnited States
-
Bellerophon Pulse TechnologiesCompletedPulmonary Arterial Hypertension | Pulmonary HypertensionUnited States, Canada
-
Allegheny Singer Research Institute (also known...CompletedPulmonary Arterial HypertensionUnited States
-
Dong-A ST Co., Ltd.CompletedFunctional DyspepsiaKorea, Republic of
-
Chong Kun Dang PharmaceuticalCompleted
-
Galderma R&DCompletedAtopic DermatitisPhilippines, China